Want to see BSEM full AI Analyst Report?
BSEM Stock Chart & Stats
$4.01
$0.18(4.59%)
At close: 4:00 PM EDT
$4.01
$0.18(4.59%)
Day’s Range― - ―
52-Week Range$2.25 - $8.40
Previous CloseN/A
Volume31.76K
Average Volume (3M)44.17K
Market Cap
$57.24M
Enterprise Value$51.44
Total Cash (Recent Filing)$6.96M
Total Debt (Recent Filing)$1.22M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Nov 17, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.66
Shares Outstanding17,832,811
10 Day Avg. Volume36,608
30 Day Avg. Volume44,172
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.63
Price to Sales (P/S)1.34
P/FCF Ratio9.67
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.00Price Target Upside74.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.95
Revenue Forecast (FY)$29.00M
Bulls Say, Bears Say
Bulls Say
Placental Tissue–derived BiologicsBioStem’s focused product set—placental allograft biologics for wound care and surgical use—represents a specialized, clinically oriented niche. Such differentiated biologics can create durable adoption in care pathways, support repeat clinical use, and build technical barriers to entry versus commodity wound-care supplies.
Positive Operating And Free Cash FlowSustained positive operating and free cash flow across recent periods provides structural flexibility: it helps fund working capital, supports continued manufacturing and commercialization, and reduces near-term reliance on dilutive financing, even as free cash flow has recently contracted.
Nasdaq Uplisting Boosts Access & VisibilityThe Nasdaq uplisting is a durable corporate improvement: it expands institutional access, improves trading liquidity, elevates visibility for partners and customers, and can assist talent recruitment and capital raising—structural supports for longer-term commercialization and scaling efforts.
Bears Say
Highly Volatile Income StatementExtreme swings from a strong 2024 to renewed losses and negative TTM revenue suggest unstable demand or execution gaps. Persistent volatility undermines predictable margins, complicates R&D and commercial planning, and increases the risk that shortfalls will erode cash cushions and strategic initiatives.
Steep Revenue And EPS DeclinesVery large year-over-year declines in revenue and EPS indicate material setbacks in commercialization or market penetration. Such declines constrain reinvestment, heighten funding needs, and may necessitate restructuring or additional financing, which can dilute shareholders and slow long-term growth plans.
Historical Balance-sheet Stress And Dilution RiskPrior periods of negative equity signal past capital shortfalls and likely dilution to shore up the balance sheet. If operating losses persist, the company remains at risk of further dilution or costly financing, which would weaken shareholder value and limit strategic optionality over the medium term.
BioStem Technologies News
BSEM FAQ
What was BioStem Technologies Inc’s price range in the past 12 months?
BioStem Technologies Inc lowest stock price was $2.25 and its highest was $8.40 in the past 12 months.
What is BioStem Technologies Inc’s market cap?
BioStem Technologies Inc’s market cap is $57.24M.
When is BioStem Technologies Inc’s upcoming earnings report date?
BioStem Technologies Inc’s upcoming earnings report date is Nov 17, 2026 which is in 91 days.
How were BioStem Technologies Inc’s earnings last quarter?
BioStem Technologies Inc released its earnings results on Aug 12, 2026. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.5 by -$0.02.
Is BioStem Technologies Inc overvalued?
According to Wall Street analysts BioStem Technologies Inc’s price is currently Undervalued.
Does BioStem Technologies Inc pay dividends?
BioStem Technologies Inc does not currently pay dividends.
What is BioStem Technologies Inc’s EPS estimate?
BioStem Technologies Inc’s EPS estimate is -0.46.
How many shares outstanding does BioStem Technologies Inc have?
BioStem Technologies Inc has 17,832,811 shares outstanding.
What happened to BioStem Technologies Inc’s price movement after its last earnings report?
BioStem Technologies Inc reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.5. Following the earnings report the stock price went down -18.421%.
Which hedge fund is a major shareholder of BioStem Technologies Inc?
Currently, no hedge funds are holding shares in BSEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioStem Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (74.56% Upside)
$7.00 (74.56% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-56.65%
Trailing 12-Months
Company Description
BioStem Technologies Inc
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
BSEM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlights strong operating execution around integration, commercial expansion, product and IP progress, sequential revenue growth (+29.5% quarter-over-quarter) and a raised revenue outlook. However, meaningful near-term financial challenges were emphasized: a $9.0 million GAAP loss, adjusted EBITDA loss, cash down to $7.0 million (≈49% decline sequentially), a $10 million contingent payment pending, and anticipated H2 margin pressure tied to legacy inventory. Management is progressing on strategic initiatives (Nasdaq uplisting, CRM/ERP integration, salesforce scale, patents, clinical data and a planned manufacturing transfer), but near-term liquidity and profitability depend on executing financing plans and the 2027 manufacturing transfer. Overall, positive operational momentum is balanced by significant near-term financial and execution risks.View all BSEM earnings summariesBSEM Stock 12 Month Forecast
Average Price Target
$7.00
▲(74.56% Upside)